The revised staging system provides a detailed common nomenclature and more clearly defines the prognosis for patients with NSCLC through the addition of many new patient subgroups and ...

Stage 3 non-small cell lung cancer has spread to nearby tissues and lymph nodes but not to more distant tissues. Most people with this stage have lung cancer symptoms. Treatment can depend on ...

One way to describe NSCLC is by its clinical or pathologic stage. Your doctor might use imaging scans to take pictures of the inside of your body to see what clinical stage the cancer is.

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It develops when abnormal lung cells grow uncontrollably, forming a tumor. There are ...

June 3, 2008 (Chicago, Illinois) — Preoperative imaging with 18 F-fluorodeoxyglucose positron emission tomography (PET) appears to more accurately identify patients with mediastinal and ...

So, in general, for early non-small cell lung cancer, we need to know what type it is, and we need to know what stage it is. So the type, the way we know, is with a biopsy. Once we know that ...

For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC) has been surgical resection, typically minimally invasive lobectomy with systematic ...

In clinical practice, traditional tumor-node-metastasis (TNM) staging has difficulty ... and recurrence monitoring of non-small cell lung cancer (NSCLC). In recent years, with the rapid progress ...

The CONVERGE study evaluates NBTXR3's efficacy in stage III unresectable NSCLC with standard chemoradiation and durvalumab. NBTXR3, a hafnium oxide nanoparticle, is activated by radiotherapy to induce ...

The revised staging system provides a detailed common nomenclature and more clearly defines the prognosis for patients with NSCLC through the addition of many new patient subgroups and ...